Cargando…
Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement
PURPOSE: To assess the effectiveness of viscosupplementation or platelet-rich plasma (PRP), compared to standard care, for pain relief after knee arthroscopic debridement in patients with meniscal pathology and osteoarthritis (OA), under normal clinical practice conditions. PATIENTS AND METHODS: We...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626376/ https://www.ncbi.nlm.nih.gov/pubmed/29026341 http://dx.doi.org/10.2147/OARRR.S138353 |
_version_ | 1783268533908537344 |
---|---|
author | Trueba Vasavilbaso, Cesáreo Rosas Bello, Carlos David Medina López, Erla Coronel Granado, Maria Pilar Navarrete Álvarez, José Mario Trueba Davalillo, Cesáreo Angel Gil Orbezo, Félix Isaac |
author_facet | Trueba Vasavilbaso, Cesáreo Rosas Bello, Carlos David Medina López, Erla Coronel Granado, Maria Pilar Navarrete Álvarez, José Mario Trueba Davalillo, Cesáreo Angel Gil Orbezo, Félix Isaac |
author_sort | Trueba Vasavilbaso, Cesáreo |
collection | PubMed |
description | PURPOSE: To assess the effectiveness of viscosupplementation or platelet-rich plasma (PRP), compared to standard care, for pain relief after knee arthroscopic debridement in patients with meniscal pathology and osteoarthritis (OA), under normal clinical practice conditions. PATIENTS AND METHODS: We conducted a prospective, randomized, evaluator-blind, pilot study. After arthroscopy, patients were randomized to receive 1) five injections of HA1 (Suprahyal(®)/Adant(®)); 2) four injections of HA2 (Orthovisc(®)); 3) three injections of HA3 (Synvisc(®)); 4) a single injection of PRP (GPS™ II); or 5) standard care (control). Patients were followed up for 18 months. Clinical outcomes were evaluated using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) at 3, 6, 12, and 18 months. Minimally Clinical Important Improvement (MCII), as relative improvement ≥20 for pain and function, was also calculated. RESULTS: Fifty patients were included. At early follow-up (3 months), total WOMAC scores improved in all groups compared to baseline with reductions of 44.79% (HA1), 24.02% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control) (p=0.002 HA1 compared to HA2). At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3). The percentage of patients achieving the MCII for both pain and function at 18 months was 100% (HA1), 80% (HA3), 60% (HA2), and 60% (PRP), whereas, in the control group, all patients returned to pre-arthroscopy levels. There were no adverse events attributable to surgery or to intraarticular administration. CONCLUSION: Viscosupplementation following arthroscopy is more effective than PRP in adequately selected patients with meniscal lesions occurring concomitantly with OA. Further controlled studies with a larger sample size and/or alternative regimens would be of interest for the scientific community. |
format | Online Article Text |
id | pubmed-5626376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56263762017-10-12 Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement Trueba Vasavilbaso, Cesáreo Rosas Bello, Carlos David Medina López, Erla Coronel Granado, Maria Pilar Navarrete Álvarez, José Mario Trueba Davalillo, Cesáreo Angel Gil Orbezo, Félix Isaac Open Access Rheumatol Original Research PURPOSE: To assess the effectiveness of viscosupplementation or platelet-rich plasma (PRP), compared to standard care, for pain relief after knee arthroscopic debridement in patients with meniscal pathology and osteoarthritis (OA), under normal clinical practice conditions. PATIENTS AND METHODS: We conducted a prospective, randomized, evaluator-blind, pilot study. After arthroscopy, patients were randomized to receive 1) five injections of HA1 (Suprahyal(®)/Adant(®)); 2) four injections of HA2 (Orthovisc(®)); 3) three injections of HA3 (Synvisc(®)); 4) a single injection of PRP (GPS™ II); or 5) standard care (control). Patients were followed up for 18 months. Clinical outcomes were evaluated using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) at 3, 6, 12, and 18 months. Minimally Clinical Important Improvement (MCII), as relative improvement ≥20 for pain and function, was also calculated. RESULTS: Fifty patients were included. At early follow-up (3 months), total WOMAC scores improved in all groups compared to baseline with reductions of 44.79% (HA1), 24.02% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control) (p=0.002 HA1 compared to HA2). At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3). The percentage of patients achieving the MCII for both pain and function at 18 months was 100% (HA1), 80% (HA3), 60% (HA2), and 60% (PRP), whereas, in the control group, all patients returned to pre-arthroscopy levels. There were no adverse events attributable to surgery or to intraarticular administration. CONCLUSION: Viscosupplementation following arthroscopy is more effective than PRP in adequately selected patients with meniscal lesions occurring concomitantly with OA. Further controlled studies with a larger sample size and/or alternative regimens would be of interest for the scientific community. Dove Medical Press 2017-09-25 /pmc/articles/PMC5626376/ /pubmed/29026341 http://dx.doi.org/10.2147/OARRR.S138353 Text en © 2017 Trueba Vasavilbaso et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Trueba Vasavilbaso, Cesáreo Rosas Bello, Carlos David Medina López, Erla Coronel Granado, Maria Pilar Navarrete Álvarez, José Mario Trueba Davalillo, Cesáreo Angel Gil Orbezo, Félix Isaac Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement |
title | Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement |
title_full | Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement |
title_fullStr | Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement |
title_full_unstemmed | Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement |
title_short | Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement |
title_sort | benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626376/ https://www.ncbi.nlm.nih.gov/pubmed/29026341 http://dx.doi.org/10.2147/OARRR.S138353 |
work_keys_str_mv | AT truebavasavilbasocesareo benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement AT rosasbellocarlosdavid benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement AT medinalopezerla benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement AT coronelgranadomariapilar benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement AT navarretealvarezjosemario benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement AT truebadavalillocesareoangel benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement AT gilorbezofelixisaac benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement |